BofA Securities analyst Travis Steed maintains $Intuitive Surgical (ISRG.US)$ with a buy rating, and maintains the target price at $550.
According to TipRanks data, the analyst has a success rate of 65.1% and a total average return of 7.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intuitive Surgical (ISRG.US)$'s main analysts recently are as follows:
Intuitive Surgical's Q3 earnings surpassed expectations, signaling a robust quarter bolstered by the placement of Da Vinci 5 systems, significant procedure volume growth, and consistent margin management. The company has revised its FY24 procedure volume growth forecast to a range of 16%-17%, with the adjusted lower end accounting for potential declines in bariatric procedures and persisting challenges in Asia, including ongoing physician strikes in Korea, while the upper end presumes stability in bariatric procedures and no escalation of headwinds in Korea and China.
The expectation is that the Street may be anticipating a significant revenue outperformance for FY25. This is following the company's quarterly report, after which projections for FY25 earnings per share were moderately increased by approximately 3%.
Intuitive Surgical's third-quarter performance was robust, surpassing projections in key areas such as DV5 placements and procedure growth. Post-launch growth momentum is significant, following the U.S. da Vinci 5 approval, with early uptake surpassing that of the fourth-generation system. These strong growth indicators hint at a potential uptick in acceleration by 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Travis Steed維持$直覺外科公司 (ISRG.US)$買入評級，維持目標價550美元。
根據TipRanks數據顯示，該分析師近一年總勝率為65.1%，總平均回報率為7.3%。
此外，綜合報道，$直覺外科公司 (ISRG.US)$近期主要分析師觀點如下：
直覺外科公司的第三季度收入超出預期，表明放置了達芬奇5系統，手術量顯著增長以及持續的邊際管理支持的強勁季度。公司已將FY24手術量增長預測修訂爲16%-17%的區間，調整後的下限考慮了減少的肥胖手術量和在亞洲持續挑戰，包括韓國持續的醫生罷工，而上限則假設肥胖手術的穩定和韓國和中國風險不升級。
有預期指出，市場可能在FY25年預計營業收入將有顯著的超預期表現。這是在公司季度報告之後，在FY25年每股收益預測略微增加約3%之後。
直覺外科公司的第三季度表現強勁，超出了關鍵領域的預期，如DV5放置和手術量增長。在美國達芬奇5獲批後，後續增長勢頭顯著，早期接受程度超過了第四代系統。這些強勁的增長因子暗示着2025年可能會加速上升。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
